As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Chemomab Therapeutics Ltd. The largest reported stake is HBM Healthcare Investments (Cayman) Ltd.'s, at 12.5%. 9 filings are on record since August 7, 2025 (Schedule 13D/A, September 9, 2026).
Who owns Chemomab Therapeutics Ltd.?
Sell to companies like Chemomab Therapeutics Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: HBM Healthcare Investments (Cayman) Ltd. · Sole voting: 80,971,680 · Shared voting: 0 · Sole dispositive: 80,971,680 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-09
- · Reporting person: Touchstone Global Investments Pty Ltd · Sole voting: 377,814 · Shared voting: 0 · Sole dispositive: 377,814 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-13
- · Holder: Otto Erik · Percent: 1.2% · Shares: 90,000 · SCHEDULE 13G/A
- · Holder: HBM Healthcare Investments (Cayman) Ltd. · Percent: 12.5% · SCHEDULE 13D
- · Holder: Peter Thiel · Percent: 4.6% · SCHEDULE 13G/A
Chemomab Therapeutics Ltd. has 9 Schedule 13D or 13G filings on record since 2025-08-07. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd. | 12.5% | 80,971,680 | SCHEDULE 13D/A, 2026-09-09 | 2026-09-07 |
| Touchstone Global Investments Pty Ltd | 5.2% | 377,814 | SCHEDULE 13G, 2026-08-13 | 2026-08-07 |
| 4.6% | 22,631,200 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 | |
| 3.2% | 13,213,260 | SCHEDULE 13G/A, 2025-08-07 | 2025-07-31 | |
| 1.2% | 90,000 | SCHEDULE 13G/A, 2026-08-10 | 2026-08-10 |
Holding shares or following this stake? See who's behind Chemomab Therapeutics Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Chemomab Therapeutics Ltd. and the records around it.
Chemomab Therapeutics Ltd. elsewhere on the record
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: ALX ONCOLOGY HOLDINGS INC (May 2026), IO Biotech, Inc. (Apr 2026), Upstream Bio, Inc. (Nov 2025)
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
Watch Chemomab Therapeutics Ltd.
Get an email when Chemomab Therapeutics Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Chemomab Therapeutics Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Chemomab Therapeutics Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Chemomab Therapeutics Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd. | 80,971,680 | 0 | 80,971,680 | 0 | SCHEDULE 13D/A, 2026-09-09 |
| Touchstone Global Investments Pty Ltd | 377,814 | 0 | 377,814 | 0 | SCHEDULE 13G, 2026-08-13 |
| Otto Erik | 90,000 | — | 90,000 | — | SCHEDULE 13G/A, 2026-08-10 |
The latest filing identifies Chemomab Therapeutics Ltd. by CUSIP 16385C203 and gives its principal executive office as KIRYAT ATIDIM, BUILDING 7, Tel Aviv (SCHEDULE 13D/A, 2026-09-09).
Purpose of Transaction (Item 4)
HBM Healthcare Investments (Cayman) Ltd.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On September 7, 2026, HBM sent formal notice to the Issuer of its election to exercise its Pre-Funded Warrants in order to effectuate its voting obligations under the Shareholder Support Agreement (as defined and described in the Original Schedule 13D).Item 4 of the SCHEDULE 13D/A filed 2026-09-09
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Morgan Stanley | 8.4% | SCHEDULE 13G |
| 2025-08-07 | Morgan Stanley | 3.2% | SCHEDULE 13G/A |
| 2025-08-11 | Otto Erik | 8.1% | SCHEDULE 13G/A |
| 2026-02-10 | Otto Erik | 6.3% | SCHEDULE 13G/A |
| 2026-02-17 | Peter Thiel | 4.6% | SCHEDULE 13G/A |
| 2026-07-16 | HBM Healthcare Investments (Cayman) Ltd. | 12.5% | SCHEDULE 13D |
| 2026-08-10 | Otto Erik | 1.2% | SCHEDULE 13G/A |
| 2026-08-13 | Touchstone Global Investments Pty Ltd | 5.2% | SCHEDULE 13G |
| 2026-09-09 | HBM Healthcare Investments (Cayman) Ltd. | 12.5% | SCHEDULE 13D/A |
Questions about who owns Chemomab Therapeutics Ltd.
Who owns Chemomab Therapeutics Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Chemomab Therapeutics Ltd.: HBM Healthcare Investments (Cayman) Ltd. (12.5%, Schedule 13D/A, filed 2026-09-09) and Touchstone Global Investments Pty Ltd (5.2%, Schedule 13G, filed 2026-08-13).
Who are the largest shareholders of Chemomab Therapeutics Ltd.?
By the share each holder's latest filing reports, the largest holders of Chemomab Therapeutics Ltd. on this page are HBM Healthcare Investments (Cayman) Ltd. (12.5%) and Touchstone Global Investments Pty Ltd (5.2%).
When did HBM Healthcare Investments (Cayman) Ltd. buy into Chemomab Therapeutics Ltd.?
The filings give report dates, not purchase dates. The earliest filing from HBM Healthcare Investments (Cayman) Ltd. on this page is the Schedule 13D, filed 2026-07-16, reporting 12.5%; its latest, Schedule 13D/A filed 2026-09-09, reports 12.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Chemomab Therapeutics Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.